dusigitumab

Ligand id: 7749

Name: dusigitumab

References
1. Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J et al.. (2014)
Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors.
Clin. Cancer Res., 20 (18): 4747-57. [PMID:25024259]
2. Raeber O, Gazit-Bornstein G, Yang X, Cartlidge SA, Tonge DW. 
Insulin-like growth factor antibodies and uses thereof.
Patent number: US7939637. Assignee: Medimmune Limited. Priority date: 13/12/2005. Publication date: 10/05/2011.